This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fontaine, G. Articles by Prost-Squarcioni, C. Search for Related Content PubMed PubMed Citation Articles by Fontaine, G. Articles by Prost-Squarcioni, C. Related Collections Ablation/ICD/surgery Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2004;109:1445-1447.)
© 2004 American Heart Association, Inc.

Focused Perspectives

Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Cardiomyopathies

Guy Fontaine, MD, PhD; Catherine Prost-Squarcioni, MD, PhD

From the Institut de Cardiologie, Hôpital de la Salpêtrière, Paris, France.

Correspondence to Institut de Cardiologie, Hôpital de la Salpêtrière, 47 Boulevard de l’Hôpital, 75013 Paris, France. E-mail guy.fontaine@bct.ap-hop-paris.fr

Key Words: Focused Perspectives • cardiomyopathy • arrhythmia • defibrillation • cardioversion

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
In the present issue of Circulation, Wichter et al¹ report the largest single-center experience demonstrating the benefit of implantable cardiac defibrillators (ICDs) in the treatment of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). The patients seem well defined, and they meet the task force criteria. In addition, 50 of 60 patients have had the diagnosis confirmed by endocardial biopsy. Advances in molecular biology and genetics, however, suggest that the term ARVC encompasses a large spectrum of diseases with similar clinical presentations and histological features. This was discussed in part in a previous editorial in Circulation.² Recent information suggests that there is an overlap in the different forms of diseases included under the general term ARVC.

See p 1503

	Terminology

 
The term right ventricular cardiomyopathy, which was introduced by the World Heart Federation and World Health Organization in 1996 in the new classification of cardiomyopathies, was selected to encompass arrhythmogenic right ventricular dysplasia (ARVD) and several other clinical entities, some of them known by a different name. In the classical article by Marcus et al,³ the term right ventricular dysplasia was taken from a book chapter on reentrant arrhythmias published in 1977.⁴ This work reported the results of antiarrhythmic surgery in young male patients with good left ventricular function who had ventricular tachycardia (VT) originating in the right ventricle. The term dysplasia was chosen because the right ventricle of 3 operated patients was covered by fat. The remaining myocardium was present only in the subendocardium. This striking feature, . . . [Full Text of this Article]

This article has been cited by other articles:

				A. Nava, B. Bauce, C. Basso, W. Dewilde, Y. Vandekerckhove, A. Bol, K. Nasir, C. Bomma, H. Tandri, A. Roguin, et al. Letters Regarding Article by Nasir et al, "Electrocardiographic Features of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy According to Disease Severity: A Need to Broaden Diagnostic Criteria" * Letters Regarding Article by Nasir et al, "Electrocardiographic Features of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy According to Disease Severity: A Need to Broaden Diagnostic Criteria" * Response Circulation, July 26, 2005; 112(4): e68 - e69. [Full Text] [PDF]

				K. A. Hodgkinson, P. S. Parfrey, A. S. Bassett, C. Kupprion, J. Drenckhahn, M. W. Norman, L. Thierfelder, S. N. Stuckless, E. L. Dicks, W. J. McKenna, et al. The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5) J. Am. Coll. Cardiol., February 1, 2005; 45(3): 400 - 408. [Abstract] [Full Text] [PDF]

				J.-S. Hulot, X. Jouven, J.-P. Empana, R. Frank, and G. Fontaine Natural History and Risk Stratification of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Circulation, October 5, 2004; 110(14): 1879 - 1884. [Abstract] [Full Text] [PDF]

				Long-Term ICD Benefits in High-Risk Patients with Arrhythmogenic RV Dysplasia Journal Watch Cardiology, May 21, 2004; 2004(521): 4 - 4. [Full Text]